What is the influence of tumor removal on the serum level of carbohydrate's antibody?October 08, 2008Cancer immune surveillance is considered to be important in the anti-tumor protection of the host. The growing tumor escapes the immune control under the immunosuppressive conditions. The surgical removal of the tumor may reverse the immunosuppression. The TF antigen and Tn belong to tumor-associated carbohydrate antigens (TACA). TF antigen is implicated in the metastatic spread due to the adhesion of cancer cells to the endothelium. However, the dynamic changes of the level of TF and Tn-antibodies in the serum of patients with cancer and its association with survival have been insufficiently studied. A research article to be published on July 21, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Dr. Kurtenkov from National Institute for Health Development (Tallinn, Estonia) have undertaken a long-term follow-up of cancer patients to determine changes in the postoperative level of TF- and Tn antibodies, as well as to elucidate the association of this level with the progression of cancer, and survival. The level of antibodies in serum was determined by the ELISA using synthetic polyacrylamide (PAA) glycoconjugates. They found that in gastrointestinal cancer, the TF antibody level was found to have elevated significantly after the removal of G3 tumors as compared with the preoperative level (u = 278.5, P < 0.05). After surgery, the TF and Tn antibody level was elevated in the majority of gastric cancer patients (sign test, 20 vs 8, P < 0.05, and 21 vs 8, P < 0.05, respectively). In gastrointestinal cancer, the elevated postoperative level of TF, Tn and Gal antibodies was noted in most patients with G3 tumors (sign test, 22 vs 5, P < 0.01; 19 vs 6, P < 0.05; 24 vs 8, P < 0.01, respectively), but the elevation was not significant in patients with G1 + G2 resected tumors. The postoperative follow-up showed that the percentage of patients with G3 resected tumors of the digestive tract, who had a mean level of anti-TF IgG above the cutoff value (1.53), was significantly higher than that of patients with G1 + G2 resected tumors (chi2 = 3.89, all patients; chi2 = 5.34, patients without regional lymph node metastases; P < 0.05). The percentage of patients with a tumor in stage I, whose mean anti-TF IgG level remained above the cut-off value (1.26), was significantly higher than that of patients with the cancer in stages II I-IV (chi2 = 4.71, gastric cancer; chi2 = 4.11, gastrointestinal cancer; P < 0.05). The correlation was observed to exist between the level of anti-TF IgG and the count of lymphocytes (r = 0.517, P < 0.01), as well as between the level of anti-Tn IgG and that of serum CA 19-9 (r = 0.481, P < 0.05). No positive delayed-type hypersensitivity reaction in skin test challenges with TF-PAA in any of the fifteen patients, including those with a high level of anti-TF IgG, was observed. Their result indicated that the surgical operation raises the level of anti-carbohydrate IgG in most patients, especially in those with the G3 tumor of the gastrointestinal tract. The stage and morphology-dependent immuneosuppression affects the TF-antibody response and may be one of the reasons for unresponsiveness to the immunization with TF-antigens. World Journal of Gastroenterology |
|||||||||||||||||||||
| Related Immunosuppressive Current Events and Immunosuppressive News Articles Switching immunosuppressants reduces cancer risk in kidney Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA. Multivisceral transplant survival rates improve with new treatment, says Pittsburgh study Data from the largest single-center experience of adult and pediatric intestinal and multivisceral transplantation show that survival rates have improved with the advent of innovative surgical techniques, novel immunosuppressive protocols and better post-operative management. Researchers link inflammatory diseases to increased cardiovascular risk Patients suffering from two serious autoimmune disorders which cause muscular inflammation are at increased risk of developing cardiovascular disease. Trojan horse for ovarian cancer -- nanoparticles turn immune system soldiers against tumor cells In a feat of trickery, Dartmouth Medical School immunologists have devised a Trojan horse to help overcome ovarian cancer, unleashing a surprise killer in the surroundings of a hard-to-treat tumor. Post-transplant combo can replace toxic immune-suppressing drugs in monkeys Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects. Immune cells ameliorate hypertension-induced cardiac damage in mice Researchers in Berlin, Germany have found that a specific type of immune cell, the regulatory T lymphocyte (Treg) plays an important role in hypertension-induced cardiac damage. Why do people with Down syndrome have less cancer? Most cancers are rare in people with Down syndrome, whose overall cancer mortality is below 10 percent of that in the general population. Study suggests TB screening needs to be targeted for maximum public health benefit New estimates of the likelihood that a latent case of tuberculosis (TB) will become active have resulted in a roughly 50 percent increase over previous estimates of the number of people needed to be screened (NNS) to prevent an active infection, limiting the cost effectiveness of screening in many Center for Disease Control and Prevention (CDC)-defined risk groups. Popular cancer drug linked to often fatal brain virus The 57-year-old lawyer in New York had handily completed the New York Times' Saturday crossword puzzle - the hardest of the week - for years. But one Saturday morning, suddenly he couldn't retrieve the words to fill in the squares. Two targeted therapies likely better than one in patients with aggressive lymphoma When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG). More Immunosuppressive Current Events and Immunosuppressive News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||